1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC : Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial
- Contribution to journal › Article
-
Mark
In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC
- Contribution to journal › Article
- 2019
-
Mark
Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC
Edlund, Karolina ; Madjar, Katrin ; Mattsson, Johanna S.M. ; Djureinovic, Dijana ; Lindskog, Cecilia ; Brunnström, Hans LU
; Koyi, Hirsh
; Brandén, Eva
; Jirström, Karin
LU
and Pontén, Fredrik
, et al.
(2019)
In Journal of Thoracic Oncology
14(4).
p.628-640
- Contribution to journal › Article
- 2018
-
Mark
An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1–Positive Lung Adenocarcinomas
Miyashita, Naoya ; Horie, Masafumi ; Suzuki, Hiroshi I. ; Yoshihara, Masahito ; Djureinovic, Dijana ; Persson, Johan ; Brunnström, Hans LU
; Lindskog, Cecilia
; Elfving, Hedvig
and Micke, Patrick
, et al.
(2018)
In Journal of Thoracic Oncology
13(11).
p.1676-1691
- Contribution to journal › Article